Dermapharm Holding SE
XETRA:DMP

Watchlist Manager
Dermapharm Holding SE Logo
Dermapharm Holding SE
XETRA:DMP
Watchlist
Price: 37.8 EUR -0.53%
Market Cap: 2B EUR
Have any thoughts about
Dermapharm Holding SE?
Write Note

Dermapharm Holding SE
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dermapharm Holding SE
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Dermapharm Holding SE
XETRA:DMP
Operating Expenses
-€543.3m
CAGR 3-Years
-18%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
ATAI Life Sciences NV
NASDAQ:ATAI
Operating Expenses
-$125.8m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Operating Expenses
-€24.7B
CAGR 3-Years
-2%
CAGR 5-Years
0%
CAGR 10-Years
-5%
Merck KGaA
XETRA:MRK
Operating Expenses
-€8.8B
CAGR 3-Years
-3%
CAGR 5-Years
-2%
CAGR 10-Years
-4%
MPH Health Care AG
XETRA:93M1
Operating Expenses
-€1.2m
CAGR 3-Years
-11%
CAGR 5-Years
0%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Operating Expenses
-€67m
CAGR 3-Years
-16%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
No Stocks Found

Dermapharm Holding SE
Glance View

Market Cap
2B EUR
Industry
Pharmaceuticals

In the bustling world of pharmaceuticals, Dermapharm Holding SE stands as a noteworthy player, crafting a narrative of strategic growth and innovation. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm presents itself as a vertically integrated pharmaceutical company whose operations stretch from development and production to marketing and distribution. This integration allows them to maintain control over their value chain, ensuring efficiency and quality across diverse product lines. Dermapharm's portfolio spans over 900 active pharmaceutical ingredients, health products, and medical devices, fortified through keenly orchestrated acquisitions that enhance their market presence and product offerings. Such strategic steps enable Dermapharm to leverage established brands while venturing into new sectors, reinforcing its reputation as a dynamic force in the pharmaceutical landscape. Dermapharm primarily generates revenue by capitalizing on dermatological products, allergy treatments, systemic corticosteroids, and vitamin supplements. By addressing a broad spectrum of chronic and everyday health conditions, they serve both niche and mass-market demands across Europe. Dermapharm’s distinctive approach combines robust in-house research and development with targeted acquisitions, such as their acquisition of the Dr. Loges-Schuten pharmaceutical company, broadening their reach into phyto-pharmaceuticals and other sectors. Additionally, Dermapharm collaborates with partners to penetrate new geographical markets, thereby diversifying their revenue streams. Such initiatives underscore the company's agility and strategic foresight, ensuring sustained growth in a competitive industry.

DMP Intrinsic Value
43.76 EUR
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Dermapharm Holding SE's Operating Expenses?
Operating Expenses
-543.3m EUR

Based on the financial report for Sep 30, 2024, Dermapharm Holding SE's Operating Expenses amounts to -543.3m EUR.

What is Dermapharm Holding SE's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-17%

Over the last year, the Operating Expenses growth was -5%. The average annual Operating Expenses growth rates for Dermapharm Holding SE have been -18% over the past three years , -17% over the past five years .

Back to Top